CNBC – RFK Jr.’s peptide policy could boost Hims & Hers as its GLP-1 business evolves

by

Hims stock price growth 25% since the peptide meeting day is set

KEY POINTS

  • Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health.
  • Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited.
  • The FDA review process is only just beginning, with a Pharmacy Compounding Advisory Committee meeting scheduled for July 2026.

Full link: https://www.cnbc.com/amp/2026/04/16/rfk-jr-peptides-hims-hers-glp-1.html